resource-limited countries. [4] [5] [6] [7] [8] [9] [10] [11] Theoretically, CD4 counting could be performed using the PIMA analyzer on finger-prick blood specimens with less invasive procedure and a very small blood specimen per test required, thus enabling it to be used where trained phlebotomists are not available or when difficulties are encountered with venous blood sampling. Here, we report the performance of PIMA analyzers at two voluntary counseling and testing (VCT) sites in Yunnan Province and compare the results with the routine CD4 analysis performed in well-equipped laboratories.
Methods

Study participants and CD4 cell counting
This study used convenience sampling of blood from HIV-infected people aged 6-65 years attending VCT sites at the Yunnan Provincial Center for Disease Control and Prevention (CDC) in Kunming city and the Dehong prefecture CDC in Dehong city between May 2012 and September 2012 as part of routine CD4 monitoring. Participants 18 years or older provided written informed consent, those younger than 18 years had written informed consent provided by their legal guardians. Demographic information collected included gender and birth date.
Three PIMA CD4 analyzers were placed at each VCT site. Finger-prick blood specimens were collected using Sarstedt lancets provided by Alere and analyzed immediately on site using a PIMA analyzer. Venous blood specimens (2 ml) were drawn in a K 3 -EDTA Vacutainer tube, and 25 μl blood tested with a PIMA analyzer on site within one hour of blood draw. The remaining venous blood was tested with FACSCalibur (Becton Dickinson, Franklin Lakes, NJ, USA) according to manufacturer's instructions in the adjacent laboratory within 2 h of blood draw. A study participant was assumed to yield 3 CD4 results from venous blood with FACSCalibur, venous blood with PIMA, and finger-prick blood with PIMA. Only the CD4 test result from venous blood tested by FACSCalibur was reported to the participant. To examine the reproducibility of the PIMA analyzer results, venous blood specimens from the first 66 and 51 participants in Kunming and Dehong, respectively, were tested at VCT sites in duplicate.
This study was approved by the Ethical Review Committees of the Chinese National Center for AIDS/STD Control and Prevention and the U.S. CDC.
Quality controls
Voluntary counseling and testing counselors and technicians who used the PIMA analyzers received half-day training from Alere technical experts on finger-prick sampling techniques and proper operation of the PIMA analyzer. A quality test was conducted with 2 PIMA internal quality control cartridges with predefined low and high CD4 counts prior to commencing testing each day, as required by the manufacturer. PIMA analyzers with quality control cartridge results within predefined ranges were used to test specimens from study participants. The cartridge with study participant's blood sample also has additional control features. The analyzer will report an invalid result if there is inappropriateness in cartridge expiry date, sample volume, reagent validation, and instrument function. The project officers and Alere technical experts in Beijing made supervisory site visits during the study. Study staffs in VCT sites were instructed to record mistakes or malfunctioning of PIMA analyzers. Daily calibration and internal quality controls were also performed on the FACSCalibur instrument. The two provincial and prefectural CD4 laboratories have fulfilled the CD4 laboratory establishment and management criteria required by the Chinese HIV laboratory management guidelines. [12] 
Statistical analysis
Data were analyzed using SAS 9.1 (SAS Institute Inc., Cary, NC, USA) for correlation coefficients and linear regressions to estimate the correlation between CD4 counts obtained by the PIMA analyzer and FACSCalibur. Bias and limits of agreement (LOA) were analyzed using the Bland-Altman method [13] to determine whether the methods agree sufficiently. Relative bias was expressed as a percentage of the difference between CD4 counts obtained by the two methods divided by the average of the measurements. To determine accuracy of the PIMA analyzer, the mean of the two measurements, mean of bias, and relative bias were obtained for different CD4 ranges (≤200, 201-350, 351-500, and >500 cells/μl). Polynomial contrasts were used to test for trends of relative bias across the whole range. FACSCalibur CD4 results were used as the reference for the calculation of sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for the PIMA analyzer. The precision of PIMA CD4 results was calculated as the mean percent coefficient of variation (CV) with the first 66 and 51 duplicates at VCT sites. All statistical tests were two-sided at alpha = 0.05.
results
Between May and September 2012, 462 HIV-1 infected persons receiving routine CD4 testing agreed to participate in this study. The mean age of the participants was 38.0 years (standard deviation 11.2, range: 7-65 years) and 61.9% were male. Four (1.0%) were under 18 years old. One incidence of FACSCalibur instrument failure resulted in the loss of data from 9 participants in Dehong. In addition, 57 participants' finger-prick PIMA detection yielded invalid results, and laboratory staff did not test the corresponding venous blood using the PIMA analyzers in Dehong. These participants were excluded from the analyses for the venous blood measurement (n = 396). An additional nine participants in Kunming had invalid finger-prick blood results. These participants did have venous blood results by both PIMA and FACSCalibur. Specimens from 387 persons had values available for finger-prick blood analysis.
Quality assurance and reproducibility of PIMA
As part of routine quality assurance, PIMA analyzers underwent daily testing using manufacturer-supplied internal quality control cartridges. CD4 counts of the low and high internal quality control cartridges were 151-281 cells/μl and 623-1157 cells/μl, respectively. All PIMA analyzers produced cartridges results within the predefined ranges for the entire study period. The average of the low cartridges was 213 cells/μl (n = 333, range 151-257 cells/μl) with a CV of 12.3%. The average of the high cartridges was 904 cells/μl (n = 297, range 790-1014 cells/μl) with a CV of 5.1%.
In the beginning of the study, 117 venous blood specimens were tested in duplicate on the PIMA analyzers. These included 66 specimens from Kunming and 51 from Dehong VCT sites. The first CD4 result obtained for each participant correlated well with their corresponding second CD4 results. The R 2 values of the two measurements were 0.93 for Kunming and 0.96 for Dehong. No statistical difference was observed in bias of the duplicate measurements at the two VCT sites. Regression analysis on all specimens showed a correlation with a R 2 = 0.94 and y = 0.97x + 10.11 (data not shown). Bland-Altman analysis showed a small overall mean bias of 1.4 cells/μl (LOA: −96.7-97.0 cells/μl) and a CV of 10.4%.
Comparison of CD4 results of venous blood by PIMA and FACSCalibur
There were 396 specimens with venous blood specimens tested by FACSCalibur and the PIMA analyzer. Regression analysis showed results correlated well with a R 2 of 0.91 (y = 0.83x + 21.89 [ Figure 1a] ). However, CD4 counts derived from PIMA were lower than those from FACSCalibur (P < 0.001) as shown by the lower slope in Figure 1a and the Bland-Altman analysis plot [ Figure 1b] . The overall mean relative bias was − 10.9% [ Table 1 ]. To better examine bias over the entire CD4 cell count range, we divided cell counts into four groups (≤200, 201-350, 351-500, and >500 cells/μl) and found the respective relative bias expanded from −2.9%, −9.9%, −14.0%, to −15.3%. The relative bias was significantly higher in groups with CD4 counts higher than 200 cells/μl than that in groups with CD4 counts ≤200 cells/μl (P < 0.001) [ Table 1 ].
Comparison of CD4 results of finger-prick blood by PIMA and venous blood by FACSCalibur
We evaluated the correlation between CD4 results of finger-prick blood by PIMA analyzers and corresponding venous blood by the referent FACSCalibur. The R 2 was 0.81 (y = 0.74x + 30.52, Figure 2a ), lower than that observed when using venous blood for both methods [ Figure 1a] . The PIMA CD4 finger-prick results were lower than the corresponding FACSCalibur venous blood specimens (P < 0.001) with LOA between −295 and 153 cells/μl, an overall bias of −71.0 cells/μl [ Figure 2b ] and an overall relative bias of −18.6% [ Table 2 ]. When cell counts were again divided into four groups, the relative bias was −9.7%, −14.2%, −20.1%, and −27.7%, respectively. The relative bias was significantly higher in groups with CD4 counts higher than 350 cells/μl compared with that in groups with CD4 counts lower than 350 cells/μl (P < 0.001) [ Table 2 ]. Results obtained with finger-prick blood using the PIMA analyzer exhibited more bias from reference values than results from venous blood using PIMA.
Comparison of CD4 results of finger-prick and venous blood by PIMA
Lastly, we compared the performance of PIMA analyzers using venous and finger-prick blood specimens. This analysis used results obtained from the 387 participants with both types of the blood specimen. The correlation was R 2 = 0.82 (y = 0.87x + 22.14) (data not shown). Finger-prick blood yielded lower CD4 counts than when using venous blood. A Bland-Altman plot revealed that the overall bias was −22.9 cells/μl (LOA: 213-167 cells/μl) (P < 0.001) (data not shown). The mean total relative bias was −7.5 ± 29.8%, individual bias for the four CD4 groups increased from −2.6% to −13.6% (P < 0.05).
Positive and negative predictive values of CD4 results from PIMA
In China, the current CD4 threshold used for ART eligibility is 350 cells/μl. Recently, WHO recommended raising the threshold for eligibility to 500 cells/μl. [14] Thus, we examined Here, we demonstrated the PIMA analyzer can provide more reliable CD4 counts using venous blood than finger-prick blood, which is consistent with previous reports. [4, 5] A potential reason for the lower CD4 counts could be excessive squeezing of a participant's finger to obtain sufficient blood. Another contributor to the PIMA analyzer's poor performance with finger-prick blood may be due to inadequate filling of the blood intake channel in the PIMA cartridge which would yield an invalid report. Our study yielded an average of 14.3% invalid reports with finger-prick blood, similar to studies previously conducted in South Africa (6.8%) [6] and Thailand (23%). [7] The lancet used for PIMA is designed to have a deeper hypodermic cut than lancets typically used in other programs, and thus the VCT staff might not perform finger-pricking correctly. However, in our study, we did not record these events. In order to improve the success of CD4 measurement using finger-prick blood, it is important to provide intensive and frequent training on the sampling technique to VCT site staff. Since phlebotomy is commonly practiced in China, even in rural VCT sites, the use of venous blood for PIMA CD4 counting was well accepted in this study and is not expected to constitute a barrier to implementation.
The PIMA analyzer consistently yielded CD4 counts lower than the referent FACSCalibur, with relative bias increasing with higher CD4 counts, as previously observed. [5, [7] [8] [9] At higher cell numbers, CD4 cells might aggregate resulting in underestimation by the PIMA analyzer. However, recent reports from India and Zimbabwe did not observe this effect. [10, 11] Our data also showed an elevated negative variation at the high end of CD4 [ Figures 1 and 2] . Using a threshold of 350 cells/μl, our data on venous blood specimens showed a PPV and NPV of 84.2% and 97.6%, respectively. When the threshold was set at 500 cells/μl, the respective values were 90.3% and 94.3%. PIMA misclassified 10% and 9% of participants using the thresholds of 350 and 500 cells/μl, respectively. Because of the bias toward lower estimation, nearly 90% of PIMA-misclassified participants had lower counts than reference and thus would result in their earlier entry to ART treatment. Although there is a concern over the early ART initiation, which might increase the financial cost, the current international recognition of the benefit of early treatment for the patients and to reduce HIV transmission outweighs this concern. Given the encouraging results of the PIMA analyzer using venous blood, this POC method will be expanded to remote Chinese areas, especially those with ethnic minorities, to improve CD4 services and identify treatment-eligible patients in a timely fashion. However, when performing CD4 counting for patient treatment monitoring, it is recommended not to switch between PIMA device and current FACSCalibur. This is the first study to evaluate the usefulness and feasibility of using a POC CD4 technology in Yunnan Province, China. The Alere PIMA analyzer provides satisfactory CD4 counting using venous blood, but is less reliable when finger-prick blood is used. However, other factors that may affect the performance of PIMA analyzer remained to be determined. Given the frequent use of phlebotomy in rural areas in China, the PIMA POC CD4 analyzer using venous blood could play an important role in improving HIV care and treatment in resource-limited settings in China. 
